Renata Medical
Renata Medical Raises $25M Series D for Pediatric Cardiovascular Devices
Renata Medical announced $25M in Series D financing on August 19, 2026. Renata Medical raised a $25 million Series D led by ARCHIMED to expand U.S. commercialization of its Minima Stent System and advance pediatric heart disease technologies.
Round details
The financing includes backing from ARCHIMED. The company did not publish a valuation with the announcement.
- Round: Series D
- Capital announced: $25M
How the company plans to use the capital
Renata Medical said proceeds will support expanded U.S. commercialization of the Minima Stent System and entry into international markets. The funds will also advance its pediatric congenital heart disease pipeline and continued clinical evidence generation.
Why this matters for GTM teams
ARCHIMED, a healthcare-focused investment firm, led the round with participation from existing investors. Renata Medical’s chief executive said adoption of the Minima Stent System has exceeded the company’s expectations since its commercial launch in 2024.
Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.
Source and methodology
This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.
Primary source: Renata Medical Series D announcement.
Company Info
Investors (1)
Share
Related Reports
Wabi Raises $55M at $1.25B Valuation in IVP-Led Funding
Wabi announced $55 million in funding led by IVP at a $1.25 billion valuation, which it said will support continued product development and expansion.
StimCardio Raises $30M Series A for Wearable AF Therapeutic
StimCardio announced the closing of an oversubscribed $30 million Series A led by Metis Medtech, expected to fund the company through its planned NeuroPulse 2 pivotal study and preparation for an FDA De Novo submission.
Casap Raises $56M Series B for AI Agents in Financial Services
Casap raised a $56 million Series B led by Base10 Partners, with Experian and Synchrony participating, to advance its AI agent platform for financial services.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started